[{"id":"463587d3-e808-4685-9d40-3926117c11c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06654050","created_at":"2025-02-25T12:31:09.116Z","updated_at":"2025-02-25T12:31:09.116Z","phase":"Phase 2","brief_title":"Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma","source_id_and_acronym":"NCT06654050","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BAP1","pipe":"","alterations":" ","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alrizomadlin (APG-115)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-24"},{"id":"9e19f934-321f-4e6c-b066-71f0217f0bae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03041688","created_at":"2021-01-18T14:58:33.453Z","updated_at":"2025-02-25T12:26:38.524Z","phase":"Phase 1","brief_title":"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT03041688","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation • Chr del(17p) • TP53 wild-type","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(17p) • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 02/08/2018","start_date":" 02/08/2018","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-24"},{"id":"593b542b-470d-465e-ae6a-8f9b079a6849","acronym":"ALLIANCE-ABTC-1604","url":"https://clinicaltrials.gov/study/NCT03107780","created_at":"2021-01-18T15:18:36.892Z","updated_at":"2025-02-25T13:48:22.462Z","phase":"Phase 1","brief_title":"Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer","source_id_and_acronym":"NCT03107780 - ALLIANCE-ABTC-1604","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • MGMT","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/09/2018","start_date":" 07/09/2018","primary_txt":" Primary completion: 03/21/2019","primary_completion_date":" 03/21/2019","study_txt":" Completion: 02/07/2026","study_completion_date":" 02/07/2026","last_update_posted":"2025-02-21"},{"id":"c9d1a579-ede0-4060-a970-738063622323","acronym":"","url":"https://clinicaltrials.gov/study/NCT03654716","created_at":"2021-01-18T17:56:08.387Z","updated_at":"2025-02-25T14:40:01.342Z","phase":"Phase 1","brief_title":"Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer","source_id_and_acronym":"NCT03654716","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • MDM2 • TET2 • SMARCB1 • PPM1D","pipe":" | ","alterations":" TP53 wild-type • TET2 mutation","tags":["TP53 • MDM2 • TET2 • SMARCB1 • PPM1D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • sulanemadlin (ALRN-6924)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 07/17/2023","study_completion_date":" 07/17/2023","last_update_posted":"2025-02-14"},{"id":"9ce1ae1c-3677-40b4-81f0-ce916a71323c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02633059","created_at":"2025-09-06T20:42:42.259Z","updated_at":"2025-09-06T20:42:42.259Z","phase":"Phase 1/2","brief_title":"Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma","source_id_and_acronym":"NCT02633059","lead_sponsor":"Mayo Clinic","biomarkers":" GDF15","pipe":"","alterations":" ","tags":["GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ninlaro (ixazomib) • idasanutlin (RG7388)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 12/30/2015","start_date":" 12/30/2015","primary_txt":" Primary completion: 01/31/2021","primary_completion_date":" 01/31/2021","study_txt":" Completion: 11/01/2022","study_completion_date":" 11/01/2022","last_update_posted":"2024-09-12"},{"id":"9795b4cb-6f73-4ce5-a9a8-6ba8acc8d386","acronym":"Keynote MK-3475-B66","url":"https://clinicaltrials.gov/study/NCT03611868","created_at":"2021-01-18T17:45:12.835Z","updated_at":"2025-02-25T16:08:10.551Z","phase":"Phase 1/2","brief_title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","source_id_and_acronym":"NCT03611868 - Keynote MK-3475-B66","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" ATM mutation • TP53 wild-type","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ATM mutation • TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 08/29/2018","start_date":" 08/29/2018","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2024-07-19"},{"id":"8c5b3516-4a7c-4205-ad40-e97eec56da64","acronym":"","url":"https://clinicaltrials.gov/study/NCT03940352","created_at":"2021-01-18T19:24:11.865Z","updated_at":"2024-07-02T16:34:27.521Z","phase":"Phase 1","brief_title":"HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT03940352","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • sabatolimab (MBG453) • siremadlin (HDM201)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/24/2019","start_date":" 06/24/2019","primary_txt":" Primary completion: 06/14/2024","primary_completion_date":" 06/14/2024","study_txt":" Completion: 06/14/2024","study_completion_date":" 06/14/2024","last_update_posted":"2024-06-11"},{"id":"1532ca3a-2502-4dd2-b1ac-69ae84a9d9a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04785196","created_at":"2021-03-05T12:55:16.352Z","updated_at":"2024-07-02T16:34:37.707Z","phase":"Phase 1/2","brief_title":"APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors","source_id_and_acronym":"NCT04785196","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" MDM2 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Loqtorzi (toripalimab-tpzi) • alrizomadlin (APG-115)"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 05/26/2021","start_date":" 05/26/2021","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2024-06-06"},{"id":"c26f7e4c-301c-4f7a-9c9b-fcbebe86dda6","acronym":"NRG-DT001","url":"https://clinicaltrials.gov/study/NCT03217266","created_at":"2021-01-18T15:52:30.675Z","updated_at":"2024-07-02T16:35:02.993Z","phase":"Phase 1","brief_title":"Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma","source_id_and_acronym":"NCT03217266 - NRG-DT001","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • MDM2 • MDM4 • CD4","pipe":"","alterations":" ","tags":["TP53 • MDM2 • MDM4 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 08/27/2023","primary_completion_date":" 08/27/2023","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-17"},{"id":"95af92d3-7ef1-42bc-8075-503c2a4324fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03975387","created_at":"2021-01-18T19:33:08.305Z","updated_at":"2024-07-02T16:35:05.855Z","phase":"Phase 1/2","brief_title":"Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53","source_id_and_acronym":"NCT03975387","lead_sponsor":"Astex Pharmaceuticals, Inc.","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 wild-type • MDM2 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MDM2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASTX295"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-06"},{"id":"1b5d9f87-d4b4-4b3b-8ef1-2a68d62c516d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05155709","created_at":"2021-12-14T13:53:59.134Z","updated_at":"2024-07-02T16:35:06.537Z","phase":"Phase 1","brief_title":"A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.","source_id_and_acronym":"NCT05155709","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • siremadlin (HDM201)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 05/17/2022","start_date":" 05/17/2022","primary_txt":" Primary completion: 05/28/2024","primary_completion_date":" 05/28/2024","study_txt":" Completion: 05/28/2024","study_completion_date":" 05/28/2024","last_update_posted":"2024-05-02"},{"id":"8626d796-d31d-4f11-a4ab-8ea3dce4cf77","acronym":"","url":"https://clinicaltrials.gov/study/NCT03725436","created_at":"2021-01-18T18:15:21.875Z","updated_at":"2024-07-02T16:35:08.781Z","phase":"Phase 1","brief_title":"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors","source_id_and_acronym":"NCT03725436","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A","pipe":" | ","alterations":" ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification","tags":["HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • sulanemadlin (ALRN-6924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-04-18"},{"id":"23fbfd55-0bea-4321-83e6-d320991b3c5c","acronym":"AMPHISARC","url":"https://clinicaltrials.gov/study/NCT05180695","created_at":"2022-01-06T22:53:30.960Z","updated_at":"2025-02-25T15:54:18.762Z","phase":"Phase 1/2","brief_title":"HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas","source_id_and_acronym":"NCT05180695 - AMPHISARC","lead_sponsor":"Centre Leon Berard","biomarkers":" MDM2","pipe":" | ","alterations":" TP53 wild-type","tags":["MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pazopanib • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 04/15/2022","start_date":" 04/15/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-04-08"},{"id":"ba5e9c1f-9156-4368-acb2-f775396afb8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04029688","created_at":"2021-01-18T19:46:44.421Z","updated_at":"2024-07-02T16:35:12.360Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors","source_id_and_acronym":"NCT04029688","lead_sponsor":"Hoffmann-La Roche","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • cyclophosphamide • topotecan • idasanutlin (RG7388) • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 01/27/2020","start_date":" 01/27/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-03-29"},{"id":"2d84bdc7-c6f6-41e1-b766-7bba4beee15a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03031730","created_at":"2021-01-18T14:55:20.440Z","updated_at":"2024-07-02T16:35:14.475Z","phase":"Phase 1","brief_title":"Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma","source_id_and_acronym":"NCT03031730","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • CD4","pipe":" | ","alterations":" TP53 mutation","tags":["TP53 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • carfilzomib • dexamethasone • navtemadlin (KRT-232) • Hemady (dexamethasone tablets)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/14/2018","start_date":" 06/14/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-15"},{"id":"d63d90c7-ce00-45f0-be6c-08cf85a450c7","acronym":"MANTRA-4","url":"https://clinicaltrials.gov/study/NCT06090318","created_at":"2023-10-19T17:12:57.672Z","updated_at":"2024-07-02T16:35:32.632Z","phase":"Phase 1b/2","brief_title":"Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss","source_id_and_acronym":"NCT06090318 - MANTRA-4","lead_sponsor":"Rain Oncology Inc","biomarkers":" TP53 • CDKN2A","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • CDKN2A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • milademetan (RAIN-32)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 05/30/2023","study_completion_date":" 05/30/2023","last_update_posted":"2023-10-19"},{"id":"81882457-ba1a-48b0-8054-a1df3a396386","acronym":"TRAHD","url":"https://clinicaltrials.gov/study/NCT03714958","created_at":"2021-01-18T18:12:34.191Z","updated_at":"2025-02-25T15:43:15.903Z","phase":"Phase 1","brief_title":"Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type","source_id_and_acronym":"NCT03714958 - TRAHD","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • TP53 • NRAS • HRAS","pipe":" | ","alterations":" TP53 mutation • BRAF mutation • TP53 wild-type • HRAS mutation","tags":["KRAS • TP53 • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BRAF mutation • TP53 wild-type • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • siremadlin (HDM201)"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 12/20/2018","start_date":" 12/20/2018","primary_txt":" Primary completion: 09/12/2023","primary_completion_date":" 09/12/2023","study_txt":" Completion: 09/12/2023","study_completion_date":" 09/12/2023","last_update_posted":"2023-09-13"},{"id":"0a3b1baf-6e1d-473c-832a-6e95be260fa7","acronym":"APG-115-US-001","url":"https://clinicaltrials.gov/study/NCT02935907","created_at":"2021-01-18T14:25:00.156Z","updated_at":"2024-07-02T16:36:07.447Z","phase":"Phase 1","brief_title":"APG-115 in Patients With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT02935907 - APG-115-US-001","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alrizomadlin (APG-115)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 06/28/2019","primary_completion_date":" 06/28/2019","study_txt":" Completion: 06/28/2019","study_completion_date":" 06/28/2019","last_update_posted":"2022-07-12"},{"id":"7581583e-6318-4ab9-9ba7-a352be1b7dec","acronym":"KRT-232-117","url":"https://clinicaltrials.gov/study/NCT04835584","created_at":"2022-04-24T09:03:04.624Z","updated_at":"2024-07-02T16:36:15.052Z","phase":"Phase 1b/2","brief_title":"KRT-232 and TKI Study in Chronic Myeloid Leukemia","source_id_and_acronym":"NCT04835584 - KRT-232-117","lead_sponsor":"Kartos Therapeutics, Inc.","biomarkers":" ABL1 • BCR","pipe":" | ","alterations":" TP53 wild-type","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • nilotinib • navtemadlin (KRT-232)"],"overall_status":"Recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 05/07/2021","start_date":" 05/07/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2022-03-21"},{"id":"a599bd6d-bb48-4886-a056-1c6c4c34af61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02343172","created_at":"2021-01-18T11:08:16.439Z","updated_at":"2024-07-02T16:36:37.589Z","phase":"Phase 1","brief_title":"Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma","source_id_and_acronym":"NCT02343172","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CDK4 • GDF15 • CDKN1A","pipe":"","alterations":" ","tags":["CDK4 • GDF15 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kisqali (ribociclib) • siremadlin (HDM201)"],"overall_status":"Completed","enrollment":" Enrollment 74","initiation":"Initiation: 03/13/2015","start_date":" 03/13/2015","primary_txt":" Primary completion: 10/16/2019","primary_completion_date":" 10/16/2019","study_txt":" Completion: 10/16/2019","study_completion_date":" 10/16/2019","last_update_posted":"2020-12-09"},{"id":"613e409a-9659-4396-bba3-22b9a39d0fcd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01877382","created_at":"2021-01-18T08:26:57.296Z","updated_at":"2024-07-02T16:36:37.709Z","phase":"Phase 1","brief_title":"A Phase 1 Multiple Ascending Dose Study of Milademetan in Subjects With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT01877382","lead_sponsor":"Daiichi Sankyo, Inc.","biomarkers":" TP53 • MDM2 • GDF15","pipe":" | ","alterations":" TP53 mutation • MDM2 amplification • MDM2 overexpression","tags":["TP53 • MDM2 • GDF15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • MDM2 amplification • MDM2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e milademetan (RAIN-32)"],"overall_status":"Completed","enrollment":" Enrollment 108","initiation":"Initiation: 07/01/2013","start_date":" 07/01/2013","primary_txt":" Primary completion: 10/08/2020","primary_completion_date":" 10/08/2020","study_txt":" Completion: 12/03/2020","study_completion_date":" 12/03/2020","last_update_posted":"2020-12-08"},{"id":"592b7eaa-b0b9-44ec-a9e0-7a40a914198a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02264613","created_at":"2021-01-18T10:39:31.889Z","updated_at":"2024-07-02T16:36:43.300Z","phase":"Phase 1/2","brief_title":"ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT02264613","lead_sponsor":"Aileron Therapeutics, Inc.","biomarkers":" TP53 • MDM2 • CDK4","pipe":" | ","alterations":" TP53 wild-type • MDM2 amplification • CDK4 amplification","tags":["TP53 • MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MDM2 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sulanemadlin (ALRN-6924)"],"overall_status":"Completed","enrollment":" Enrollment 149","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2020-07-14"},{"id":"ce98ee02-21d8-47cc-adbf-beb7c12bd1ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT03760445","created_at":"2021-01-18T18:28:53.713Z","updated_at":"2024-07-02T16:36:51.542Z","phase":"Phase 1/2","brief_title":"HDM201 Added to CT in R/R or Newly Diagnosed AML","source_id_and_acronym":"NCT03760445","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • PML","pipe":" | ","alterations":" FLT3 mutation","tags":["FLT3 • PML"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e midostaurin • Vyxeos (cytarabine/daunorubicin liposomal formulation) • idarubicin hydrochloride • siremadlin (HDM201) • Noxafil (posaconazole) • midazolam hydrochloride"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/15/2019","start_date":" 11/15/2019","primary_txt":" Primary completion: 07/22/2021","primary_completion_date":" 07/22/2021","study_txt":" Completion: 06/13/2023","study_completion_date":" 06/13/2023","last_update_posted":"2020-01-09"},{"id":"b98cd67d-2012-4eee-853b-5c1f66a8faed","acronym":"","url":"https://clinicaltrials.gov/study/NCT02909972","created_at":"2021-01-18T14:16:56.352Z","updated_at":"2024-07-02T16:36:53.442Z","phase":"Phase 1","brief_title":"Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome","source_id_and_acronym":"NCT02909972","lead_sponsor":"Aileron Therapeutics, Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • sulanemadlin (ALRN-6924)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2019-11-19"}]